drugset / Trial / NCT01318551

Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects

NCT01318551

Phase 1 Completed 56 enrolled Bayer
Non-randomizedSingle-groupOpen-labelOther

Summary

Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single dose group stratified study in renal impaired and healthy subjects.

Timeline

Start
2011-03-16
Primary completion
2013-09-05
Completion
2014-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Molidustat Small molecule 20 mg Oral
Subject Molidustat Small molecule 40 mg Oral
Subject Molidustat Small molecule 80 mg Oral

Indications